These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 24440664)

  • 1. Lung gene therapy with highly compacted DNA nanoparticles that overcome the mucus barrier.
    Suk JS; Kim AJ; Trehan K; Schneider CS; Cebotaru L; Woodward OM; Boylan NJ; Boyle MP; Lai SK; Guggino WB; Hanes J
    J Control Release; 2014 Mar; 178():8-17. PubMed ID: 24440664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-acetylcysteine enhances cystic fibrosis sputum penetration and airway gene transfer by highly compacted DNA nanoparticles.
    Suk JS; Boylan NJ; Trehan K; Tang BC; Schneider CS; Lin JM; Boyle MP; Zeitlin PL; Lai SK; Cooper MJ; Hanes J
    Mol Ther; 2011 Nov; 19(11):1981-9. PubMed ID: 21829177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Highly compacted DNA nanoparticles with low MW PEG coatings: in vitro, ex vivo and in vivo evaluation.
    Boylan NJ; Suk JS; Lai SK; Jelinek R; Boyle MP; Cooper MJ; Hanes J
    J Control Release; 2012 Jan; 157(1):72-9. PubMed ID: 21903145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of airway gene transfer by DNA nanoparticles using a pH-responsive block copolymer of polyethylene glycol and poly-L-lysine.
    Boylan NJ; Kim AJ; Suk JS; Adstamongkonkul P; Simons BW; Lai SK; Cooper MJ; Hanes J
    Biomaterials; 2012 Mar; 33(7):2361-71. PubMed ID: 22182747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PEGylated enhanced cell penetrating peptide nanoparticles for lung gene therapy.
    Osman G; Rodriguez J; Chan SY; Chisholm J; Duncan G; Kim N; Tatler AL; Shakesheff KM; Hanes J; Suk JS; Dixon JE
    J Control Release; 2018 Sep; 285():35-45. PubMed ID: 30004000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanocomplexes for gene therapy of respiratory diseases: Targeting and overcoming the mucus barrier.
    Di Gioia S; Trapani A; Castellani S; Carbone A; Belgiovine G; Craparo EF; Puglisi G; Cavallaro G; Trapani G; Conese M
    Pulm Pharmacol Ther; 2015 Oct; 34():8-24. PubMed ID: 26192479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Model of mucociliary clearance in cystic fibrosis lungs.
    Kurbatova P; Bessonov N; Volpert V; Tiddens HA; Cornu C; Nony P; Caudri D;
    J Theor Biol; 2015 May; 372():81-8. PubMed ID: 25746843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhaled gene therapy of preclinical muco-obstructive lung diseases by nanoparticles capable of breaching the airway mucus barrier.
    Kim N; Kwak G; Rodriguez J; Livraghi-Butrico A; Zuo X; Simon V; Han E; Shenoy SK; Pandey N; Mazur M; Birket SE; Kim A; Rowe SM; Boucher R; Hanes J; Suk JS
    Thorax; 2022 Aug; 77(8):812-820. PubMed ID: 34697091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Highly compacted biodegradable DNA nanoparticles capable of overcoming the mucus barrier for inhaled lung gene therapy.
    Mastorakos P; da Silva AL; Chisholm J; Song E; Choi WK; Boyle MP; Morales MM; Hanes J; Suk JS
    Proc Natl Acad Sci U S A; 2015 Jul; 112(28):8720-5. PubMed ID: 26124127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-clinical evaluation of three non-viral gene transfer agents for cystic fibrosis after aerosol delivery to the ovine lung.
    McLachlan G; Davidson H; Holder E; Davies LA; Pringle IA; Sumner-Jones SG; Baker A; Tennant P; Gordon C; Vrettou C; Blundell R; Hyndman L; Stevenson B; Wilson A; Doherty A; Shaw DJ; Coles RL; Painter H; Cheng SH; Scheule RK; Davies JC; Innes JA; Hyde SC; Griesenbach U; Alton EW; Boyd AC; Porteous DJ; Gill DR; Collie DD
    Gene Ther; 2011 Oct; 18(10):996-1005. PubMed ID: 21512505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PEGylation for enhancing nanoparticle diffusion in mucus.
    Huckaby JT; Lai SK
    Adv Drug Deliv Rev; 2018 Jan; 124():125-139. PubMed ID: 28882703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimization of hCFTR lung expression in mice using DNA nanoparticles.
    Padegimas L; Kowalczyk TH; Adams S; Gedeon CR; Oette SM; Dines K; Hyatt SL; Sesenoglu-Laird O; Tyr O; Moen RC; Cooper MJ
    Mol Ther; 2012 Jan; 20(1):63-72. PubMed ID: 21952168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CFTR delivery to 25% of surface epithelial cells restores normal rates of mucus transport to human cystic fibrosis airway epithelium.
    Zhang L; Button B; Gabriel SE; Burkett S; Yan Y; Skiadopoulos MH; Dang YL; Vogel LN; McKay T; Mengos A; Boucher RC; Collins PL; Pickles RJ
    PLoS Biol; 2009 Jul; 7(7):e1000155. PubMed ID: 19621064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution.
    Konstan MW; Davis PB; Wagener JS; Hilliard KA; Stern RC; Milgram LJ; Kowalczyk TH; Hyatt SL; Fink TL; Gedeon CR; Oette SM; Payne JM; Muhammad O; Ziady AG; Moen RC; Cooper MJ
    Hum Gene Ther; 2004 Dec; 15(12):1255-69. PubMed ID: 15684701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Cystic Fibrosis-Like Airway Surface Layer Is not a Significant Barrier for Delivery of Eluforsen to Airway Epithelial Cells.
    Brinks V; Lipinska K; de Jager M; Beumer W; Button B; Livraghi-Butrico A; Henig N; Matthee B
    J Aerosol Med Pulm Drug Deliv; 2019 Oct; 32(5):303-316. PubMed ID: 31120356
    [No Abstract]   [Full Text] [Related]  

  • 16. Hybrid Lipid/Polymer Nanoparticles to Tackle the Cystic Fibrosis Mucus Barrier in siRNA Delivery to the Lungs: Does PEGylation Make the Difference?
    Conte G; Costabile G; Baldassi D; Rondelli V; Bassi R; Colombo D; Linardos G; Fiscarelli EV; Sorrentino R; Miro A; Quaglia F; Brocca P; d'Angelo I; Merkel OM; Ungaro F
    ACS Appl Mater Interfaces; 2022 Feb; 14(6):7565-7578. PubMed ID: 35107987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid transport of muco-inert nanoparticles in cystic fibrosis sputum treated with N-acetyl cysteine.
    Suk JS; Lai SK; Boylan NJ; Dawson MR; Boyle MP; Hanes J
    Nanomedicine (Lond); 2011 Feb; 6(2):365-75. PubMed ID: 21385138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unplugging Mucus in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease.
    Mall MA
    Ann Am Thorac Soc; 2016 Apr; 13 Suppl 2():S177-85. PubMed ID: 27115954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring Mechanisms of Lipid Nanoparticle-Mucus Interactions in Healthy and Cystic Fibrosis Conditions.
    Tafech B; Rokhforouz MR; Leung J; Sung MM; Lin PJ; Sin DD; Lauster D; Block S; Quon BS; Tam Y; Cullis P; Feng JJ; Hedtrich S
    Adv Healthc Mater; 2024 Jul; 13(18):e2304525. PubMed ID: 38563726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanoparticle diffusion in respiratory mucus from humans without lung disease.
    Schuster BS; Suk JS; Woodworth GF; Hanes J
    Biomaterials; 2013 Apr; 34(13):3439-46. PubMed ID: 23384790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.